PVI
ATXS

Pura Vida Investments’s Astria Therapeutics ATXS Stock Holding History

Pura Vida Investments’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,085
Closed -$119K – 156
2020
Q2 		$119K Buy
3,085
+67
+2% +$2.39K 0.01% 119
2020
Q1 		$75K Buy
+3,018
New +$93.6K 0.01% 92

Other funds holding ATXS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pura Vida Investments's ATXS Position: Q3 2020 in Review

Pura Vida Investments sold out of Astria Therapeutics (ATXS) in Q3 2020, closing a stake of 3,085 shares — an estimated $119K sold.

Pura Vida Investments first reported a position in ATXS in Q1 2020 and held it in 2 quarters. The position peaked at $119K in Q2 2020. 51 funds tracked by Wall St. Rank hold ATXS as of Q3 2020.

  • Pura Vida Investments reported no remaining Astria Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Pura Vida Investments sold 3,085 Astria Therapeutics shares in Q3 2020, an estimated $119K.
  • Pura Vida Investments first reported a position in Astria Therapeutics in Q1 2020 and held it in 2 quarters.
  • Pura Vida Investments's Astria Therapeutics position peaked at $119K in Q2 2020.
  • 51 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2020.

Based on Pura Vida Investments's 13F filing for Q3 2020, filed 16 Nov 2020.